全文获取类型
收费全文 | 568篇 |
免费 | 32篇 |
学科分类
医药卫生 | 600篇 |
出版年
2022年 | 2篇 |
2021年 | 10篇 |
2020年 | 3篇 |
2019年 | 8篇 |
2018年 | 15篇 |
2017年 | 10篇 |
2016年 | 7篇 |
2015年 | 8篇 |
2014年 | 9篇 |
2013年 | 11篇 |
2012年 | 28篇 |
2011年 | 31篇 |
2010年 | 18篇 |
2009年 | 24篇 |
2008年 | 39篇 |
2007年 | 34篇 |
2006年 | 42篇 |
2005年 | 31篇 |
2004年 | 31篇 |
2003年 | 31篇 |
2002年 | 28篇 |
2001年 | 36篇 |
2000年 | 28篇 |
1999年 | 23篇 |
1998年 | 5篇 |
1997年 | 10篇 |
1996年 | 4篇 |
1995年 | 6篇 |
1994年 | 1篇 |
1993年 | 4篇 |
1992年 | 8篇 |
1991年 | 6篇 |
1990年 | 9篇 |
1989年 | 9篇 |
1988年 | 3篇 |
1987年 | 7篇 |
1986年 | 5篇 |
1985年 | 5篇 |
1984年 | 1篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1973年 | 5篇 |
1972年 | 1篇 |
排序方式: 共有600条查询结果,搜索用时 62 毫秒
91.
92.
Thuy B. Tran MD Lauren M. Postlewait MD Shishir K. Maithel MD Jason D. Prescott MD PhD Tracy S. Wang MD MPH Jason Glenn MD John E. Phay MD Kara Keplinger MD Ryan C. Fields MD Linda X. Jin MD Sharon M. Weber MD Ahmed Salem MD Jason K. Sicklick MD Shady Gad MD Adam C. Yopp MD John C. Mansour MD Quan‐Yang Duh MD Natalie Seiser MD PhD Carmen C. Solorzano MD Colleen M. Kiernan MD Konstantinos I. Votanopoulos MD Edward A. Levine MD Ioannis Hatzaras MD Rivfka Shenoy MD Timothy M. Pawlik MD MPH PhD Jeffrey A. Norton MD George A. Poultsides MD 《Journal of surgical oncology》2016,114(8):971-976
93.
94.
95.
96.
97.
98.
BACKGROUND: The extent to which inhaled glucocorticoids increase the risk of intraocular pressure elevation has been controversial. OBJECTIVE: The authors attempt to assess such risk attributable to budesonide, an inhaled glucocorticoid for asthma therapy. METHODS: Data were pooled from four prospective, randomized, double-blind, parallel-group, placebo-controlled, multicenter clinical trials of 12 to 20 weeks in duration. One thousand two hundred and fifty-five patients, 6 to 70 years of age whose intraocular pressures (IOPs) were less than 23 mmHg at screening were randomized to receive placebo or inhaled budesonide at doses ranging from 100 to 800 microg, administered twice daily. Intraocular pressure was measured at screening and at the end of double-blind treatment. Intraocular change was compared between budesonide and placebo, accounting for the confounding effects of gender, race, age, history of diabetes, history of hypertension, clinical trial, systemic glucocorticoid use during the trials, ophthalmic glucocorticoid use during the trials, and prior oral glucocorticoid use. RESULTS: No budesonide treatment effect on the IOP was evident either in the crude analysis or after adjustment for possible confounding factors. For patients exposed to budesonide at a total daily dose of 1600 microg for 20 weeks, there was no difference in IOP change compared with the placebo controls. CONCLUSIONS: No association with an increased IOP was observed in asthmatic patients treated with budesonide at daily doses ranging from 200 to 1600 microg for durations of 12 to 20 weeks. The subgroup analysis, which focused on the highest dose and longer term therapy was reassuring, as was the overall result. 相似文献
99.
Ivan Ovald Dragan Boi
evi Lidija Duh Ivana Vinkovi Vr
ek Ivan Pavi
i Ana-Marija Domijan Mirta Mili 《Nutrients》2021,13(12)
Although a very-low-calorie diet (VLCD) is considered safe and has demonstrated benefits among other types of diets, data are scarce concerning its effects on improving health and weight loss in severely obese patients. As part of the personalized weight loss program developed at the Duga Resa Special Hospital for Extended Treatment, Croatia, we evaluated anthropometric, biochemical, and permanent DNA damage parameters (assessed with the cytochalasin B-blocked micronucleus cytome assay—CBMN) in severely obese patients (BMI ≥ 35 kg m−2) after 3-weeks on a 567 kcal, hospital-controlled VLCD. This is the first study on the permanent genomic (in)stability in such VLCD patients. VLCDs caused significant decreases in weight (loss), parameters of the lipid profile, urea, insulin resistance, and reduced glutathione (GSH). Genomic instability parameters were lowered by half, reaching reference values usually found in the healthy population. A correlation was found between GSH decrease and reduced DNA damage. VLCDs revealed susceptible individuals with remaining higher DNA damage for further monitoring. In a highly heterogeneous group (class II and III in obesity, differences in weight, BMI, and other categories) consisting of 26 obese patients, the approach demonstrated its usefulness and benefits in health improvement, enabling an individual approach to further monitoring, diagnosis, treatment, and risk assessment based on changing anthropometric/biochemical VLCD parameters, and CBMN results. 相似文献
100.